Colorado Biotech Launches with $15 Million Financing Round

RheumaGen Inc., an Aurora-based cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced Jan. 9 the close of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The financing will support RheumaGen in completing a Phase I clinical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA).